COMPANY:

NanoString Technologies

"NanoString Technologies, Inc...and Visiopharm...announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. Together, NanoString and Visiopharm are developing integrated workflows leveraging the multiplexing capability of the GeoMx® Digital Spatial Profiler (DSP) and the AI-driven image analysis capabilities of Visiopharm. NanoString’s new cloud informatics platform, the AtoMx™ Spatial Informatics Platform, will enhance the integration by providing scalable computing power with worldwide access."

"NanoString Technologies, Inc...announced a peer-reviewed paper published in Nature Genetics using the GeoMx Human Whole Transcriptome Atlas (WTA) to construct a high-resolution molecular landscape of pancreatic cancer. This paper, along with a tissue image generated using the GeoMx® Digital Spatial Profiler (DSP), is featured on the cover of the August 2022 edition of Nature Genetics."

"NanoString Technologies, Inc...announced the highlights of over 125 studies enabled by NanoString platforms that will be presented at the 2022 meeting of the American Association of Cancer Research (AACR), which will be held April 8-13, 2022...These abstracts include at least 36 studies exploring spatial biology using the CosMx™ Spatial Molecular Imager (SMI) and GeoMx® Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the nCounter® Analysis System."

"NanoString Technologies, Inc...today announced a peer-reviewed publication using the GeoMx® Digital Spatial Profiler (DSP), published in the journal Cell...The study, 'Spatially organized multicellular immune hubs in human colorectal cancer,'...investigated a cohort of 28 mismatch repair-proficient tumors and 34 mismatch repair-deficient colorectal cancer samples."

"NanoString Technologies, Inc...and the Parker Institute for Cancer Immunotherapy (PICI) announced today that they are collaborating on an expansive molecular characterization project for cellular therapies. The collaboration will define the characteristics that make a cell therapy effective, providing a standardized approach to developing CAR-T regimens that may improve patient outcomes across all cancer types, especially solid tumors...The collaboration will leverage the cell therapy expertise of PICI’s network, including world-class academic research centers, and empower research teams with NanoString’s widely recognized nCounter® Analysis System and CAR-T Characterization Panel."

"NanoString Technologies, Inc...today announced the highlights of spatial biology abstracts that will be presented at the 2021 meeting of the American Association of Cancer Research (AACR), which will be held virtually from April 10 - 15, 2021...At AACR 2021, eight abstracts that used GeoMx DSP will be presented during the poster session on Saturday, April 10. Four of the eight abstracts will be presented by investigators from the GeoMx Breast Cancer Consortium (GBCC), an international network of breast cancer researchers. Their goal is to apply innovative approaches and decipher the spatial context of breast cancer to develop a comprehensive atlas and database of novel biomarkers for the disease."

"NanoString Technologies…today announced the publication of a study in the journal Nature Medicinethatused NanoString’s GeoMx® Digital Spatial Profiler (DSP) and the new Whole Transcriptome Atlas (WTA) to profile sarcoma tissue. The research was led by a team from the Broad Institute in Cambridge, Massachusetts."

"NanoString Technologies, Inc...today announced the development of a spatial molecular imaging platform, a next generation solution for multiplexed analysis of RNA and protein expression for individual cells within a tissue sample."

"NanoString Technologies, Inc...today announced a collaboration with Oregon Health & Science University (OHSU) for their development of novel GeoMx® Digital Spatial Profiler (DSP) protein assays to spatially profile breast cancer. These assays will be designed to enhance breast cancer tumor analysis and may inform clinical decision-making of patient treatment options. The work will be performed under the GeoMx Translational Leadership Network (GTLN), and the newly formed GeoMx Clinical Consortium, with the goal of developing clinical applications on the GeoMx DSP platform."

"NanoString Technologies, Inc…announced the launch of GeoMx® DSP Protein Assays for next generation sequencing (NGS) readout, enabling multi-analyte analysis for both nCounter® and NGS readout…The GeoMx DSP Protein Assays for NGS readout available today include greater than 50 targets focused on immuno-oncology applications. These assays will provide GeoMx Cancer Transcriptome Atlas users complementary protein content designed for NGS readout…In addition to the launch of GeoMx Protein Assays for NGS, the company is launching three new 10-plex GeoMx Mouse Immuno-Oncology Protein Assays for readout using the nCounter Analysis System."

"Bio-Techne…and NanoString Technologies, Inc…today announced an expansion of their partnership to include compatibility with ACD's 21,000+ RNAscope probes and 10 qualified RNAscope probe combinations with GeoMx® Digital Spatial Profiler (DSP) and the recently launched GeoMx Cancer Transcriptome Atlas (CTA)."